Zhejiang Hisun Pharmaceutical Management

Management criteria checks 2/4

Zhejiang Hisun Pharmaceutical's CEO is Yan Li, appointed in Jan 2019, has a tenure of 5.33 years. directly owns 0.046% of the company’s shares, worth CN¥4.49M. The average tenure of the management team and the board of directors is 5 years and 5.6 years respectively.

Key information

Yan Li

Chief executive officer

CN¥2.7m

Total compensation

CEO salary percentage	n/a
CEO tenure	5.3yrs
CEO ownership	0.05%
Management average tenure	5yrs
Board average tenure	5.6yrs

Recent management updates

Recent updates

These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well

Apr 30

Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel

Mar 29

CEO

Yan Li (47 yo)

5.3yrs

Tenure

CN¥2,683,300

Compensation

Mr. Yan Li serves as President and Director at Zhejiang Hisun Pharmaceutical Co., Ltd. since January 24, 2019. Mr. Li was Supervisor at Kontour (Xi'an) Medical Technology Co., Ltd.from November 07, 2019 t...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Yan Li	President & Director	5.3yrs	CN¥2.68m	0.046% CN¥ 4.5m
Xiao Hua Chen	Senior VP & Vice Chairman	6.9yrs	CN¥1.70m	0.028% CN¥ 2.7m
Zhen Ying Zhang	Financial Director	5.2yrs	CN¥1.21m	0.017% CN¥ 1.6m
Hong Shun Jin	Senior Vice President	5yrs	CN¥1.26m	0.018% CN¥ 1.7m
Zhiqing Yang	Senior Vice President	5yrs	CN¥1.41m	0.021% CN¥ 2.0m
Xinghai Lu	Senior Vice President	4.3yrs	CN¥1.65m	0.019% CN¥ 1.9m
Jiaqiu Du	Director and Senior Vice President	5yrs	CN¥3.16m	0.021% CN¥ 2.0m
Xi Fei Shen	Secretary of the Board	6.6yrs	CN¥929.40k	0.013% CN¥ 1.2m

5.0yrs

Average Tenure

48.5yo

Average Age

Experienced Management: 600267's management team is seasoned and experienced (5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Yan Li	President & Director	5.3yrs	CN¥2.68m	0.046% CN¥ 4.5m
Xiao Hua Chen	Senior VP & Vice Chairman	6.9yrs	CN¥1.70m	0.028% CN¥ 2.7m
Jiaqiu Du	Director and Senior Vice President	no data	CN¥3.16m	0.021% CN¥ 2.0m
Shun Bing Yu	Chairman of the Supervisory Committee	2.3yrs	CN¥419.00k	0.0069% CN¥ 668.7k
Guoping Jiang	Chairman	5.5yrs	CN¥1.55m	0.026% CN¥ 2.5m
Baichao Zheng	Director	5.8yrs	no data	no data
Rong Fu Fei	Director	6.3yrs	no data	no data

5.6yrs

Average Tenure

49yo

Average Age

Experienced Board: 600267's board of directors are considered experienced (5.6 years average tenure).

Zhejiang Hisun Pharmaceutical Management

Management criteria checks 2/4

Key information

Recent management updates

Zhejiang Hisun Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Zhejiang Hisun Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024

These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well

Full year 2023 earnings released: CN¥0.08 loss per share (vs CN¥0.42 profit in FY 2022)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel

Investor sentiment deteriorates as stock falls 17%

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 16, 2024

Price target decreased by 13% to CN¥8.30

New minor risk - Financial position

Third quarter 2023 earnings released: EPS: CN¥0.031 (vs CN¥0.01 in 3Q 2022)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 2Q 2022)

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Full year 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.43 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.01 (vs CN¥0.19 in 3Q 2021)

Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) announces an Equity Buyback for CNY 195 million worth of its shares.

Taizhou Jiaojiang State Owned Asset Operation Group Co Ltd agreed to acquire 4% stakes in Zhejiang Hisun Animal Health-care Products Co., Ltd. from Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) for CNY 100 million.

Second quarter 2022 earnings released: EPS: CN¥0.27 (vs CN¥0.13 in 2Q 2021)

Shanghai Yuanxun Enterprise Management Center and Hong Kong Summit Nutrition Limited agreed to acquire 34.72% interest of Zhejiang Hisun Sulikang Biotechnology Co., Ltd from Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) for RMB 17.4 million.

Investor sentiment improved over the past week

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.43 (vs CN¥0.43 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.11 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.32 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.074 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.096 in FY 2019)

New 90-day low: CN¥15.49

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: CN¥18.41

CHIPSCREEN and HISUN Reach A Strategic Cooperation

New 90-day low: CN¥15.63

Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE:600267) signed letter of intent to acquire the remaining 49% stake in Hanhui Pharmaceutical Co., Ltd. from Hillhouse Capital Management, Ltd for CNY 4.4 billion.

Earnings released

New 90-day high - CN¥18.90

Zhejiang Hisun Pharmaceutical Co., Ltd. announced a financing transaction

Zhejiang Hisun Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age